Literature DB >> 12571787

Spinal muscular atrophy with progressive myoclonic epilepsy: report of new cases and review of the literature.

G Haliloglu1, A Chattopadhyay, L Skorodis, A Manzur, E Mercuri, B Talim, Z Akçören, Y Renda, F Muntoni, H Topaloğlu.   

Abstract

Spinal muscular atrophy (SMA) is a clinically and genetically heterogeneous disease characterised by loss of motor function and muscle atrophy due to anterior horn cell degeneration. The most common variant is chromosome 5-linked proximal SMA, ranging in severity from congenital onset and infantile death to onset in adult life. Genetically separate variants with different distribution of weakness and/or additional features such as central nervous system involvement have been described. A rare variant with associated myoclonic epilepsy and lower motor neuron disease had been previously described in three families before the SMN gene, responsible for the common form of SMA, was isolated. We report four patients from two additional families affected by a syndrome characterised by severe and progressive myoclonic epilepsy and proximal weakness, tremor and lower motor neuron disease proven by electrophysiologic and muscle biopsy findings. Extensive metabolic investigations were normal and genetic analysis excluded the SMN gene. This study confirms that the association of myoclonic epilepsy and motor neuron disease represents a separate clinical and genetic entity from chromosome 5-linked SMA, the primary defect of which remains unknown.

Entities:  

Mesh:

Year:  2002        PMID: 12571787     DOI: 10.1055/s-2002-37087

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  7 in total

Review 1.  The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.

Authors:  Alessandro Orsini; Angelo Valetto; Veronica Bertini; Mariagrazia Esposito; Niccolò Carli; Berge A Minassian; Alice Bonuccelli; Diego Peroni; Roberto Michelucci; Pasquale Striano
Journal:  Seizure       Date:  2019-08-23       Impact factor: 3.184

2.  Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1.

Authors:  Jie Zhou; Marcel Tawk; Francesco Danilo Tiziano; Julien Veillet; Monica Bayes; Flora Nolent; Virginie Garcia; Serenella Servidei; Enrico Bertini; Francesc Castro-Giner; Yavuz Renda; Stéphane Carpentier; Nathalie Andrieu-Abadie; Ivo Gut; Thierry Levade; Haluk Topaloglu; Judith Melki
Journal:  Am J Hum Genet       Date:  2012-06-14       Impact factor: 11.025

3.  ASAH1 variant causing a mild SMA phenotype with no myoclonic epilepsy: a clinical, biochemical and molecular study.

Authors:  Massimiliano Filosto; Massimo Aureli; Barbara Castellotti; Fabrizio Rinaldi; Domitilla Schiumarini; Manuela Valsecchi; Susanna Lualdi; Raffaella Mazzotti; Viviana Pensato; Silvia Rota; Cinzia Gellera; Mirella Filocamo; Alessandro Padovani
Journal:  Eur J Hum Genet       Date:  2016-03-30       Impact factor: 4.246

4.  Association of type IV spinal muscular atrophy (SMA) with myoclonic epilepsy within a single family.

Authors:  Damith S Liyanage; Lakmini S Pathberiya; Inuka K Gooneratne; Kumarangie K Vithanage; Ranjanie Gamage
Journal:  Int Arch Med       Date:  2014-09-26

Review 5.  Acid ceramidase deficiency: Farber disease and SMA-PME.

Authors:  Fabian P S Yu; Samuel Amintas; Thierry Levade; Jeffrey A Medin
Journal:  Orphanet J Rare Dis       Date:  2018-07-20       Impact factor: 4.123

Review 6.  Clinical and genetic diversity of SMN1-negative proximal spinal muscular atrophies.

Authors:  Kristien Peeters; Teodora Chamova; Albena Jordanova
Journal:  Brain       Date:  2014-06-25       Impact factor: 13.501

Review 7.  Metabolic Dysfunction in Spinal Muscular Atrophy.

Authors:  Marc-Olivier Deguise; Lucia Chehade; Rashmi Kothary
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.